What is Synchron?
Synchron is at the forefront of neurotechnology, specializing in the development of minimally invasive brain-computer interfaces (BCIs). Their flagship technology, the Stentrode system, is designed to provide individuals with paralysis the ability to control digital devices hands-free. Beyond assistive technologies, Synchron's work also advances next-generation neural decoding, paving the way for broader applications of brain-computer interfaces in everyday life. The company's progress indicates a strong trajectory in a rapidly evolving field.
How much funding has Synchron raised?
Synchron has raised a total of $275M across 2 funding rounds:
Series C
$75M
Series D
$200M
Series C (2022): $75M with participation from ARCH Venture Partners and Bezos Expeditions
Series D (2025): $200M led by Khosla Ventures, ARCH VENTURE PARTNERS, Double Point Ventures, and Bezos Expeditions
Key Investors in Synchron
Khosla Ventures
Khosla Ventures is a venture capital firm known for investing in breakthrough technologies across various sectors including AI, health, and robotics. They provide strategic advice to entrepreneurs, indicating a focus on companies with high-growth potential.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading early-stage venture capital firm that invests in life sciences and advanced technology companies. Their involvement suggests a strategic interest in Synchron's deep-tech and medical innovation.
Bezos Expeditions
Bezos Expeditions, founded by Jeff Bezos, makes strategic investments in diverse sectors including technology and healthcare. Their participation signals confidence in Synchron's disruptive potential and long-term market impact.
What's next for Synchron?
The substantial enterprise-level capital infusion, highlighted by the recent major strategic investment, positions Synchron for accelerated growth and further innovation. This backing is indicative of a company scaling its operations, likely focusing on clinical trials, regulatory approvals, and broader market penetration for its BCI solutions. The strategic nature of the recent financing suggests a strong belief from investors in Synchron's long-term vision and its potential to revolutionize assistive technology and neural decoding.
See full Synchron company page
